TRex Bio Prices $116.7M IPO at Bottom of Range

TL;DR: TRex Bio, a clinical-stage biotech targeting autoimmune and inflammatory disease, raised $116.7 million in a U.S. IPO, selling about 8.3 million shares at $14 each. The company had marketed the shares at $14 to $16, so it priced at the floor, according to Fierce Biotech.

I read every IPO downside first. In the Navy I signed off on more than 1,000 QA jobs, and the habit stuck: verify before you trust. A bottom-of-range price is the kind of headline people read as a verdict, so I checked what it actually shows.

What did TRex Bio actually price?

I went to the company's own pricing announcement first, which is dated the evening of October 8. It says TRex Bio priced 8,333,334 shares at $14.00, for expected gross proceeds of about $116.7 million before underwriting discounts and expenses. Trading was expected to begin on the Nasdaq Global Select Market on October 9, and the offering was expected to close on October 13.

Term	Figure	Source
Price per share	$14.00	TRex Bio press release
Marketed range	$14 to $16	Fierce Biotech
Shares sold	8,333,334	TRex Bio press release
Gross proceeds	about $116.7 million	TRex Bio press release
Underwriter option	up to 1,250,000 more shares	TRex Bio press release
Value at IPO price	about $384 million	Quartz, citing the SEC filing

The underwriter option matters if you care about total size. Fierce Biotech put the extra proceeds at around $17.5 million if the underwriters take all of it.

Why does pricing at the bottom of the range matter?

It tells you demand did not push the price up. A company that prices at the top, or above, has usually found more buyers than shares. This one found enough buyers at the lowest price it had floated. That is my read, and the filings don't say it.

The size of the slice is worth working out. Quartz reports a market value of about $384 million at the IPO price, and the raise is $116.7 million, so new public buyers are getting roughly 30% of the company. Existing holders are diluted to pay for the next stretch of trials.

The floor price is one data point. The first weeks of trading say more.

Who's behind TRex Bio, and what do I make of it?

Eli Lilly is the name that stands out. Quartz reports that Lilly indicated interest in buying shares in the offering, with a stake not expected to exceed 19.9% of outstanding shares after the IPO, per an earlier filing. I wouldn't treat that as a purchase, because an indication of interest isn't one. The final allocation is worth checking.

Separately, Fierce Biotech notes that in 2023 Lilly paid $55 million to take up its option to license an immune effector cell modulator that has since entered the clinic. In plain terms, that's a drug meant to adjust how the immune system's working cells behave.

The funding history is short. Fierce Biotech says TRex first broke cover in 2021 with a $59 million Series A, then raised an $84 million Series B in 2024 and a $50 million financing at the start of this year. It had around $91 million in the bank before the IPO.

What will the money pay for?

The company calls itself focused on tissue Treg biology. Tregs are regulatory T cells, the immune cells that calm an overactive immune response, and the idea is to build drugs that switch them on in diseased tissue.

Quartz, citing the filing, says TRex Bio plans to use net proceeds to advance its lead candidate, TRB-061, now in Phase 1b trials in moderate-to-severe atopic dermatitis. It's a tumor necrosis factor receptor 2 agonist, which is a drug that switches on one specific receptor on immune cells. Topline data from that trial is expected in mid-2027.

That date is the real checkpoint. A Phase 1b readout is early evidence. A clinical-stage company with one lead program can swing hard on a single result, and that's the downside to understand before anything else.

Common mistakes

Don't read the IPO price as a fair value call. It's the price a set of institutional buyers agreed to on one night.

A famous backer doesn't remove the risk either. Lilly's reported interest says a large drugmaker is paying attention, and it says nothing about whether the trial will work.

Mixing up access and judgment is the subtler error. Access is not an edge. Judgment is.

If you want more on how I think about this, I've written about valuation math in Cognition's $1 billion raise, about concentration risk in 137 Ventures' SpaceX bet, and about a smaller route to public markets in Regulation A+, the mini-IPO.

FAQ

When did TRex Bio IPO?

TRex Bio announced its IPO pricing in a release dated October 8, 2026. Its shares were expected to begin trading on Nasdaq on October 9 under the ticker TRXB, with closing expected October 13.

What does TRex Bio do?

It's a clinical-stage biotech focused on tissue Treg biology, developing immunoregulatory medicines, according to its pricing release on BioSpace. Its lead candidate, TRB-061, is in Phase 1b for atopic dermatitis.

Is a bottom-of-range IPO price a bad sign?

It shows demand did not lift the price above the floor. How the shares trade and what the mid-2027 trial data shows will tell you more.

The takeaway for your private-round decisions

When a private company you're looking at heads toward an IPO, read the filing for how many shares new buyers get and at what price. I send the full downside-first breakdown of deals like this in the free AIN briefing, and you can sign up for it on this page.

Educational content only. Not investment, tax, or legal advice. Not an offer or solicitation to buy or sell securities. Past performance does not guarantee future results. Private-market investments are illiquid and involve risk of loss, including total loss of capital. Consult qualified advisers. Angel Investors Network is not a broker-dealer or investment adviser.